Top 6 Factors To Consider In Your Forecasting Strategy
Pharmaceutical specialists, Dr. Carlos R. Camozzi and Ramana Sonty spoke to Pharma IQ in regards to the top 6 factors to consider in an early access programme planning strategy.
Early Access Programmes: Regulation Handbook - 2nd Edition
Ahead of this year’s Early Access Programmes Europe conference, Pharma IQ expands its regulatory handbook to develop the industry’s awareness of the various compliance requirements that surround the implementation of these programmes.
Facing The Ethical Minefield: Early Access Programmes
There are numerous ethical landmines for pharmaceutical companies to consider and navigate in running Early Access Programmes. Ahead of this year's conference, Pharma IQ spoke to Arthur Caplan, Head of Bioethics, New York University Langone Medical Center and Chairman, of the Comp ...
Early Access Programmes: Regulatory Handbook
This Pharma IQ handbook showcases the main regulatory requirements to be considered in regards to early access programmes within the EU. Including specific requirements for Austria, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, and the UK.
Early Access Programmes: Challenges and Considerations
In this Pharma IQ interview, Jose Ricardo Perez, Senior Medical Director at Novartis,highlights the biggest considerations for someone potentially looking at a new early access programme (EAP) and the key regulatory differences between the USA and Europe. Perez also reveals his top tips for someo ...
Five minutes with Vee Mapunde on: the growing influence of patient advocacy groups in Early Access Programmes
We had a chat with Vee Mapunde, Associate Consumer Lead at the National Cancer Research Institute (NCRI) on the role of patient advocacy groups in the Early Access Prorammes landscape, their missions and the tools they have to fulfill them, ahead of the Early and Managed Access Programmes confere ...
Three tips to ensure an ethical and sustainable Early Access Programme
Early and Managed Access Programmes can prolong the life of patients who have a life-threatening illness or a chronic or rare condition, by providing them access to investigational drugs. Their investigative nature does mean that ethical challenges often arise during their process. Ahead of the t ...
Additional Content Download
Convince Your Boss Letter
We appreciate that time out of the office can be difficult to justify, especially with the constant pressures of return on investment and time. With this in mind we have put together this short prospectus for you to use it in your internal decision-making process, if needed - hope it's...
Fast Track Registration Form
Fast track your attendance! Download the registration form for more information on workshops, sessions, pricing and special discounts. Plus, if you're ready to register, just fill out the form and email it to email@example.com
Managed Access Programs: Reaching Patients in Need
Navigating the MAP: Durbin offers the regulatory expertise, and vast distribution networks, to get the most out of a Managed Access Program for both patients and Biotech/ Pharmaceutical companies. Read more here.
Sample Delegate List from 2015
Download a sample of the Early Access Programmes delegate list from 2015